Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis

Robert K. Shin, Kottil W. Rammohan, Mitzi J. Williams

Research output: Contribution to journalComment/debatepeer-review


COVID-19 vaccines are safe for people living with MS on or off disease-modifying therapies and are important for the prevention of COVID-19. Antibody responses for individuals on certain DMTs may be diminished, however, T-cell responses may be preserved in those individuals. Data are lacking regarding optimal timing of vaccinations, and delaying disease-modifying therapies may increase the risk of disease activity and progression. In this perspective podcast, the authors recommend COVID-19 vaccination as soon as possible, regardless of timing considerations, in most cases. Graphical Plain Language Summary: [Figure not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)415-425
Number of pages11
JournalNeurology and Therapy
Issue number2
StatePublished - Dec 2021


  • B-cell-targeting therapy
  • Coronavirus
  • COVID-19
  • Disease modifying therapy
  • Multiple sclerosis
  • Patient education
  • SARS-CoV-2
  • Vaccines

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this